NCT05501639View on ClinicalTrials.gov

Exacerbation Risk in Asthma

CompletedOBSERVATIONAL
Enrollment

1,899

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

November 2, 2021

Study Completion Date

November 2, 2021

Conditions
Asthma
Interventions
DRUG

tiotropium

tiotropium

DRUG

long-acting β2-agonists (LABA)

long-acting β2-agonists (LABA)

DRUG

inhaled corticosteroids (ICS)

inhaled corticosteroids (ICS)

Trial Locations (1)

10601

eMax Health, White Plains

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05501639 - Exacerbation Risk in Asthma | Biotech Hunter | Biotech Hunter